| abstract |
The present invention relates to methods for treating cancer in a patient comprising the administration of a PD-1 antagonist, for example, an anti-PD-1 antibody or an antigen-binding fragment thereof (for example, pembrolizumab), in patient-specific amounts approximately every six weeks. In some embodiments, the amount of anti-PD-1 antibody or antigen-binding fragment thereof is about 400 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab or an antigen-binding fragment thereof. Compositions and kits are also provided comprising a dosage of an anti-PD-1 antibody or antigen-binding fragment thereof and uses thereof for the treatment of cancer. |